<DOC>
	<DOCNO>NCT00511706</DOCNO>
	<brief_summary>The study evaluate safety efficacy intravitreal implant dexamethasone Anti-VEGF treatment vs. Anti-VEGF alone ( sham dexamethasone injection ) patient subfoveal choroidal neovascularization secondary age-related macular degeneration .</brief_summary>
	<brief_title>Safety Efficacy New Treatment Adjunctive Therapy Anti-vascular Endothelial Growth Factor ( Anti-VEGF ) Treatment Patients With Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>50 year age old subfoveal choroidal neovascularization ( CNV ) ( classic and/or occult ) secondary AMD Visual Acuity 20/40 20/400 study eye Any intraocular surgery within 3 month Glaucoma Cataract High eye pressure Uncontrolled systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>